Pharmacokinetics of clodronate in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 14, Issue 3, 1999, Pages 699-705

  Ala Houhala, Ilpo ^a,b   Saha, Heikki ^a,b   Liukko Sipi, Sirpa ^c   Ylitalo, Pauli ^a,b   Pasternack, Amos ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Oy Leiras Finland Ab   (Finland)

Author keywords

Clodronate; Haemodialysis; Hyperparathyroidism; Pharmacokinetics

Indexed keywords

CLODRONIC ACID; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; DIALYSATE; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

EID: 0033006771     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.3.699     Document Type: Article

References (26)

1. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs 1991; 42: 919-944
2. Singer FR. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 1995; 6: 269-288
3. Russel JE, Termine JD, Avioli LV. Experimental osteodystrophy. The response to 25-hydroxycholecalciferol and dichloromethylene diphosphate therapy. J Clin Invest 1975; 56: 548-554
4. Malluche HH. The possible use of bisphosphonates in the treatment of renal osteodystrophy. Clin Nephrol 1992; 38: S87-91
5. Hamdy NAT, McKloskey EV, Brown CB, Kanis JA. Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure. Nephron 1990; 56: 6-12
6. Yakatan GJ, Poynor WJ, Talbert RL et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31: 402-410
7. Conrad KA, Lee SM. Clodronate kinetics and dynamics. Clin Pharmacol Ther 1981; 30: 114-120
8. Pentikäinen PJ, Elomaa I, Nurmi AK, Kärkkäinen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 1988; 27: 222-228
9. O'Rourke NPO, McCloskey EV, Neugebauer G, Kanis JA. Renal and nonrenal clearance of clodronate in patients with malignancy and renal impairment. Drug Invest 1994; 7: 26-33
10. Saha H, Castren-Kortekangas P, Ojanen S et al. Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 1994; 9: 1953-1958
11. Beigel AE, Rienhoff E, Olbricht CJ. Removal of clodronate by hemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 1995; 10: 2266-2268
12. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseus abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150
13. Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R. Histological, radiological and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis. Am J Nephrol 1992; 14: 19-29
14. Hene' RJ, Visser WJ, Duursma JA, De Bos Kuilt RJ, Dorhout Mees EJ. No effect of APD (amino hydroxypropylidine bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. Bone 1990; 11: 15-20
15. Yap AS, Hockings GI, Fleming SJ, Khafagi FA. Use of aminohydroxyproline bisphosphonate (AHPrBP, 'APD') for the treatment of hypercalcemia in patients with renal impairment. Clin Nephrol 1990; 34: 225-229
16. Ring T, Sodemann B, Nielsen C, Melsen F, Kornerup HJ. Mineralization defect but no effect on hypercalcemia during clodronate treatment in secondary hyperparathyroidism. Clin Nephrol 1995; 44: 209-210
17. Kanis JA, McCloskey EV. The use of clodronate in disorders of calcium and skeletal metabolism. In: Kanis JA, ed. Calcium Metabolism (Prog Basic Clin Pharmacol, Vol. 4). Karger, Basel, 1990; 89-136
18. Hanhijärvi H, Elomaa I, Karlsson M, Lauren L. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmal Ther Toxicol 1989; 27: 602-606
19. Fitton A, McTavish D. Pamindronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289-318
20. Mönkkönen J, Urtti A, Paronen P, Elo HA, Ylitalo P. The uptake of clodronate (dichloromethylene bisphosphatate) by macrophages in vivo and in vitro. Drug Metab Dispos 1989; 17: 690-693
21. Powell JH, DeMark BR. Clinical pharmacokinetics of diphosphonates. In: Garattini S, ed. Bone Reabsorption, Metastases and Diphosphonates. Raven Press, New York, 1985; 41-49
22. Saha H, Ala-Houhala I, Liukko-Sipi S, Ylitalo P, Pasternack A. Pharmacokinetics of clodronate in peritoneal dialysis patients. Peril Dial Int 1998; 18: 204-209
23. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24: 57-62
24. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19: 303-317
25. Schaefer K. Unsatisfactory control of serum phosphate: Why is it so common and what can be done? Nephrol Dial Transplant 1994; 9: 1366-1367
26. Khan SA, McKloskey KV, Eyres KS et al. Comparison of three intravenous regimens of clodronate in Paget diasease of bone. J Bone Miner Res 1996; 11: 1178-1182